Publications by authors named "Georges Caouette"
Article Synopsis
- Docosahexaenoic acid (DHA), an important omega-3 fatty acid for brain development, was studied to see if high-dose supplementation during the neonatal period could enhance behavioral functioning in very preterm children by age 5.
- In a multicenter randomized controlled trial, 177 children were assessed at 5 years, with 132 completing neurodevelopmental evaluations.
- Results showed no significant improvement in behavioral functioning or secondary outcomes for those who received DHA compared to a placebo, indicating that high-dose DHA did not have the expected positive effects.
Article Synopsis
- The study aimed to investigate if maternal high-dose DHA supplementation improved neurodevelopment in very preterm neonates at 18 to 22 months corrected age.
- A randomized, double-blind, placebo-controlled trial was conducted with lactating mothers of preterm neonates, comparing outcomes for children whose mothers took DHA-rich algae oil and those on a placebo.
- Results showed no overall improvement in cognitive, language, or motor scores between the two groups, but a notable benefit in language scores for neonates born before 27 weeks’ gestation who received DHA.
Article Synopsis
- DHA, an important omega-3 fatty acid, is investigated for its potential impact on brain development in very preterm infants through a study that supplemented high doses of DHA or placebo.
- This follow-up study aims to analyze neurodevelopmental outcomes at 5 years of age, focusing on recruitment success and various developmental assessments in preschool-aged children.
- The study has ethical approval, requires informed consent from mothers, and will take about 22 months to complete, utilizing standardized questionnaires and interviews to gather data on the children's development and maternal experiences.
Article Synopsis
- Maternal DHA supplementation might help prevent bronchopulmonary dysplasia in premature infants, but the evidence is not clear-cut.
- A clinical trial was conducted with mothers of infants born before 29 weeks, providing them either DHA or placebo capsules; it was stopped early due to potential harm concerns.
- The results showed that 54.9% of infants who received DHA survived without bronchopulmonary dysplasia, compared to 61.6% in the placebo group, suggesting no significant benefit from DHA supplementation.
Background: Infants born at 33-35 completed weeks' gestational age (wGA) aged <6 months at the start of or born during respiratory syncytial virus (RSV) season and classified as moderate/high risk of severe RSV disease were included in a palivizumab RSV prophylaxis program in the province of Quebec, Canada, until 2014-2015. We assessed the impact of withdrawal of this indication on lower respiratory tract infection (LRTI)/RSV hospitalizations (H) in this population.
Methods: We conducted a 4-year, retrospective, cohort study in 25 Quebec hospitals (2 seasons with and 2 without palivizumab prophylaxis for moderate- to high-risk infants).
Background: In 2015, the Quebec Ministry of Health limited palivizumab prophylaxis for respiratory syncytial virus (RSV) in premature infants to those born at <33 weeks gestational age (wGA), unless other indications were present. We compared RSV-related costs for 2 seasons before the change (2013-2014, 2014-2015) and 2 seasons after (2015-2016, 2016-2017) in premature infants 33-35 wGA.
Methods: Using payer and societal perspectives, costs associated with hospitalizations for RSV and lower respiratory tract infection (LRTI) in infants born at 33-35 wGA were estimated.
Background: Minimally invasive surfactant therapy (MIST) is a new strategy to avoid mechanical ventilation (MV) in respiratory distress syndrome. The primary aim of this study was to test MIST as a means of avoiding MV exposure and pneumothorax occurrence in moderate and late preterm infants (32 to 36 weeks' gestational age).
Methods: This was a randomized controlled trial including three Canadian centres.
Background: Late preterm infants (34-36 weeks' gestation) remain a population at risk for apnea of prematurity (AOP). As infants affected by respiratory distress syndrome (RDS) have immature lungs, they might also have immature control of breathing. Our hypothesis is that an association exists between RDS and AOP in late preterm infants.
View Article and Find Full Text PDFBackground: Human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) are leading pediatric pathogens. However, risk factors for severe hMPV disease remain unknown. We comparatively assessed environmental, host, and viral determinants for severe hMPV and RSV infections.
View Article and Find Full Text PDFArticle Synopsis
- Palivizumab is an antibody used to protect against severe respiratory infections caused by the human respiratory syncytial virus (HRSV).
- A study analyzed respiratory infections in children receiving palivizumab by testing nasal samples for various viruses and monitoring HRSV infections.
- Results showed that while HRSV still caused significant infections (33% of viral cases), the overall impact was mild, with most infected kids showing less severe symptoms after multiple doses of the treatment.
Objective: This randomized, controlled trial was designed to determine the efficacy of inhaled fluticasone propionate on oxygen therapy weaning in a population of preterm infants who were born at <32 weeks of gestation and experienced moderate bronchopulmonary dysplasia (BPD).
Methods: Thirty-two infants who were < or =32 weeks of gestation, had moderate BPD that required supplemental oxygen (fraction of inspired oxygen > or =0.25), and were aged between 28 and 60 days were randomized.
Background: Infants born at 33 through 35 completed weeks of gestation (33-35GA) are at risk for severe respiratory syncytial virus (RSV) infection, and palivizumab prophylaxis lowers hospitalizations for RSV infection by as much as 80%. The 33-35GA cohort comprises 3-5% of annual births; thus expert panels recommend limiting prophylaxis to situations in which frequency or health care impact of RSV infection is high. This study sought to identify independent risk factors for hospitalization for RSV infection.
View Article and Find Full Text PDF